| The S&P 500 added 0.3% on Wednesday, just a day after US markets suffered their worst selloff in years. The Nasdaq gained 0.7%, and the Dow was up 0.1% on the session. The small-cap Russell 2K advanced 0.4%. This morning, futures are in the red as we approach the opening bell. S&P 500 contracts are currently showing a 0.2% loss. Lithium Stocks In The Spotlight
An undiscovered lithium stock trading below $0.30 per share just uncovered 8 high-quality targets on unexplored ground.
Drills are turning on later this year, but very few investors know about it yet, so this ground-floor opportunity below $0.30 won't be around much longer. It's a new breed of lithium stock, and shares could be on course to explode. Get the Name and Trading Symbol Here A U.S. railroad strike has been narrowly averted after railroad operators and workers struck an 11th-hour tentative deal overnight. California's Attorney General has opened up an antitrust suit against Amazon claiming the eCommerce giant unfairly punished merchants for selling lower-priced products on competing sites. Humana Inc [HUM] - Last Close: $458.85 Humana is surging on a bullish forecast. The healthcare firm will hold a virtual Investor Day today at 8:30 a.m., but the company has already shared some big news with the public. This morning, Humana announced a new midterm adjusted EPS target of $37 for 2025, representing a 14% compounded annual growth rate over the company's updated FY 2022 EPS outlook. Humana also raised its full-year 2022 adjusted EPS to "approximately $25" at its Investor Day event. HUM is one of this morning's top S&P 500 stocks, with a 5.0% gain. My Take: HUM is coming off a pullback, but this stock could push higher if it can break past strong resistance at $500. It doesn't look like today's move is going to be enough, but it could be worth watching. Addentax Group Corp [ATXG] - Last Close: $4.78 Addentax is on the rise after a rough run in the market. The logistics provider has struggled since completing its IPO last week, but it finally looks like the slide could be bottoming out. The company's common stock began trading on the Nasdaq Capital Market on August 31st. Since then, shares are down 81.7%. However, shares prices are rebounding in today's session. ATXG is one of the most actively-traded premarket stocks today, ad it's showing a 25.1% gain. My Take: This rally is an encouraging sign for ATXG, but I don't think it's out of the water just yet. Careful you don't get caught on the wrong side of a pullback if you decided to dabble here. Neurobo Pharmaceuticals Inc [NRBO] - Last Close: $16.86 Neurobo Pharma is surging on news of a new licensing deal. South Korean pharma company Dong-A ST has agreed to license two key drugs to Neurobo Pharma in a multi-million-dollar deal. Under the terms of the deal, Neurobo will get Dong-A's exclusive global development rights for DA-1241 to treat type 2 diabetes and DA-1726 for obesity and non-alcoholic fatty hepatitis. In exchange, Dong-A will receive $22 million in upfront cash payments, plus milestones for each stage and sales-based royalties. Dong-A will also be responsible for producing clinical samples and products for commercialization. NRBO is one of today's top premarket performers with a 50.4% gain on the licensing news. My Take: Today's rally shows that the market believes these two drug candidates have potential. If they're right, NRBO could be set up for more gains down the road. However, drug trials can take years to play out sometimes, so be prepared to be patient if you decide to make a move. iMedia Brands [IMBI] - Last Close: $0.8452 A new analyst upgrade is boosting shares of iMedia Brands. This morning, B. Riley Securities upgraded IMBI to "neutral" from "buy" and announced a $5 price target on the stock. B. Riley's price target represents a 491% upside from IMBI's current price point. The analyst upgrade is pushing share prices higher in today's premarket. IMBI is one of today's top performers with a 16.7% gain. My Take: Don't put too much faith in the analyst price target, but it's worth taking note of the institutional attention this stock is getting. |
